Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
302results about How to "Lower blood lipid levels" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Use of exendins for the reduction of food intake
InactiveUS6956026B2Reduce appetiteReduce cardiac riskPeptide/protein ingredientsPharmaceutical delivery mechanismFeeding disabilityCvd risk
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:ASTRAZENECA PHARMA LP
Novel Low Molecular Weight Cationic Lipids for Oligonucleotide Delivery
ActiveUS20130090372A1Good curative effectReduce liver toxicityOrganic compound preparationOther foreign material introduction processesTolerabilityNanoparticle
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
Owner:SIRNA THERAPEUTICS INC
Nucleic acid molecules encoding WRINKLED1-like polypeptides and methods of use in plants
InactiveUS8217223B2High oil contentImprove the level ofBryophytesSugar derivativesBiotechnologyFatty acid
Owner:BASF PLANT SCI GMBH
Low molecular weight cationic lipids for oligonucleotide delivery
ActiveUS8748667B2Good curative effectReduce liver toxicityOrganic compound preparationOther foreign material introduction processesTolerabilityNanoparticle
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
Owner:SIRNA THERAPEUTICS INC
Lipids and Lipid Compositions for the Delivery of Active Agents
ActiveUS20160311759A1Good curative effectLow toxicitySsRNA viruses negative-senseOrganic active ingredientsActive agentLipid composition
Owner:NOVARTIS AG
Targeted apo CIII CRISPR-Cas 9 system and application thereof
ActiveCN105462968APromote recoveryReduce morbidityMetabolism disorderGenetic material ingredientsSecondary hyperlipidemiaGene
The invention provides a CRISPR-Cas 9 system used for preventing and / or treating hyperlipidemia and other cardiovascular diseases and a preparing method and application thereof. The CRISPR-Cas 9 system comprises an sgRNA sequence of a specific region on a specific targeting human apo CIII gene and a middle carrier comprising the sgRNA sequence, and the specific region on the apo CIII gene is selected from apo CIII gene expressed regions. The invention further provides the application of the CRISPR-Cas 9 system to preparation of drugs for preventing and / or treating hyperlipidemia and other cardiovascular diseases. By means of the prepared sgRNA of the specific targeting human apo CIII gene, the human apo CIII gene can be targeted accurately and knocked out. The preparing method is simple in step, and good in sgRNA targeting, and the knockout efficiency of the CRISPR-Cas 9 system is high.
Owner:河北仁博科技有限公司
Benzoxazepine compounds, their production and use as lipid lowering agents
InactiveUS6110909AExcellent lipid-level lowering activityLow toxicityBiocideOrganic active ingredientsHalogenHydrogen atom
PCT No. PCT / JP96 / 02596 Sec. 371 Date Mar. 12, 1998 Sec. 102(e) Date Mar. 12, 1998 PCT Filed Sep. 12, 1996 PCT Pub. No. WO97 / 10224 PCT Pub. Date Mar. 20, 1997This invention provides new benzoxazepine compounds represented by the formula: [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atom] having activities of lowering chlesterol-level and lowering trigluceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.
Owner:TAKEDA PHARMA CO LTD
Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
ActiveUS8399441B2Lower Level RequirementsImprove suppression propertiesOrganic active ingredientsMetabolism disorderLipid formationMetabolite
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Weight-loss health-care food and preparation method thereof
ActiveCN103230021AReduce emptyingHinder or delay digestion and absorptionFood preparationDiet controlledVitamin
The invention discloses a weight-loss health-care food which is prepared from the main raw materials of, by weight, 1-60% of a white kidney bean extract, 1-50% of L-malic acid, 1-65% of L-carnitine tartrate, and 1-40% of konjac powder. The invention also discloses a preparation method of the weight-loss health-care food. The method comprises the step that: the main materials of the white kidney bean extract, L-malic acid, L-carnitine tartrate, and konjac powder are well mixed, such that the health-care food with weight-loss function is obtained. With the health-care food, starchy substance absorption is inhibited, body metabolism is promoted, and energy conversion is promoted, such that fat consumption is increased, fat formation is prevented, and a weight-loss function is achieved. With the preparation method, absorption of nutrients such as proteins and vitamins is not influenced, diet control is not needed, and weight can be naturally controlled and reduced. The preparation method provided by the invention has the advantages of simple process, no high-temperature operation, convenient operation, and energy saving.
Owner:GUANGZHOU SAIJIAN BIO TECH
Composite plant solid drink suitable for diabetic patients
The invention provides a composite plant solid drink suitable for diabetic patients, hyperglycemia and fat crowds. The solid drink comprises the following components in parts by weight: 40-65 parts of grain puffing powder, 4-10 parts of medicine and food homology plant extract, 5-20 parts of functional ingredient, 0.1-0.5 part of compound vitamin and 2.5-4.5 parts of compound mineral. According to the composite plant solid drink, the 'medicine and food homology' of the traditional Chinese medicine is combined, the modern nutriology and the biological hygiene are applied, the raw material ratio and the nutrition content meet the diet requirements of the diabetic patients, namely high dietary fibers, low fat, high-quality proteins, a proper amount of vitamins and minerals can meet the nutrition meal replacement and addition demands of the diabetic patients, the diabetic complication is prevented or relieved, the solid drink can be matched with drug for treatment, the glucose fluctuation of the diabetic patients is controlled, the over-dependence of the diabetic patients on drugs is reduced, and even the glucose tolerance of the diabetic patients can be recovered.
Owner:广州金酮医疗科技有限公司
Blood lipid-lowing active fractions of forsythia suspensa and preparation method and use of same
InactiveCN101537046AImproves antioxidant activityLower blood lipid levelsOrganic chemistryMetabolism disorderChemistryAdemetionine
The invention relates to blood lipid-lowering active fractions of forsythia suspensa and a preparation method and use of the same. The active fractions are ethyl acetate fractions obtained by concentrating an extract which is extracted from forsythia suspensa leaves by acetone and water. The compound of phillygenin prepared by the invention and the active fractions, namely the ethyl acetate fractions, at which the phillygenin is positioned have good antioxidant activity in vitro. In-vivo experiments show that the ethyl acetate fractions and the phillygenin can lower total cholesterols and low-density lipoprotein cholesterin in the blood serum of a mouse with hyperlipidemia and can lower blood lipid level by an oxidative approach (raising superoxide dismutase SOD and lowering malonydialdehyde MDA). In addition, the ethyl acetate fractions have a better effect of reducing the total cholesterols in the blood serum of the mouse than the phillygenin and cassia seed blood lipid-lowering tablets. The ethyl acetate fractions of the forsythia suspensa leaves can be further developed to play a role in the multi- target co-prevention and treatment of hyperlipidemia and other diseases and have a good application prospect.
Owner:HENAN UNIVERSITY
Health-care coarse-grain flour, dried noodle, and preparation processes thereof
ActiveCN102349553AGuaranteed not to break downGuaranteed conditioning functionDough treatmentFood preparationBiotechnologyGizzard
The invention discloses health-care coarse-grain flour which is prepared from the following raw materials in parts by weight: (1) coarse cereals: 60-70 parts of wheat, 4-6 parts of corn, 4-6 parts of polished round-grained rice, and 4-6 parts of barley; (2) auxiliary raw materials: 0.2-1 parts of walnut, 0.1-0.8 parts of cattle blood, 0.15-0.6 parts of goose blood, 0.1-0.6 parts of yam, and 0.1-0.8 parts of endodermis of chicken gizzard; meanwhile, the auxiliary raw materials of the health-care coarse-grain flour disclosed by the invention further comprise0.1-0.8 parts of pig blood, 0.1-0.6 parts of edible fungus, 0.2-1 parts of peanuts, and 0.2-1 parts of cassia seeds; in addition, the coarse-grain flour also can comprises 8-12 parts of one of tapioca, broad bean meal, peameal, soybean meal and millet or sorghum flour, or an arbitrary mixture thereof. The invention discloses a process for preparing the health-care coarse-grain flour. Meanwhile, the invention also discloses a health-care coarse-grain dried noodle prepared from the health-care coarse-grain flour above and a preparation process thereof.
Owner:SHEHONG YIMIN FOOD
Low molecular weight cationic lipids for oligonucleotide delivery
ActiveUS9029590B2Good curative effectReduce liver toxicityUrea derivatives preparationOrganic active ingredientsLipid formationTolerability
The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
Owner:SIRNA THERAPEUTICS INC
Oat coarse cereals convenient rice
The invention relates to an instant rice food comprising the following raw materials (by weight ratio): oat 20-30 parts, black wheat 5-10 parts, Chinese sorghum 20-25 parts, buckwheat 15-20 parts, maize particles 15-20 parts. The food is prepared through the steps of immersing, boiling, immersing, and boiling again.
Owner:山西金绿禾燕麦研究所
Corn stalk nano-dietary fiber and method of preparing the same
The invention provides corn straw nano dietary fiber and a preparation method thereof. The method adopts cellulase-producing bacteria for pure culture or mixed bacteria cofermentation to ferment corn straws, and carries out the ultra-high pressure homogenization treatment on the fermented corn straws to obtain the nano dietary fiber through spray drying or freeze drying. The corn straws are washed by water to remove impurities, dried, crushed and sieved, mixed evenly with skim milk powder or other substances and the water, sterilized and cooled; and a single-bacterium or multi-bacteria seed liquid of the cellulase-producing bacteria is inoculated into a culture medium for fermentation, a product after the fermentation is rinsed until the pH value is neutral, and the corn straw nano dietary fiber is prepared after homogenization treatment and spray drying or freeze drying. The method has simple preparation technology, mild conditions and no pollution to the environment, and is easy for industrialized production; and the dietary fiber has exquisite taste, increases the solubility, greatly improves water retention ability, water absorptivity and expansive power, and improves the content of soluble dietary fiber by more than 50 percent.
Owner:孟繁宇
Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors
InactiveUS20080188488A1Lower blood lipid levelsEffective to modulate triglyceride levelOrganic active ingredientsOrganic chemistryDiseaseStearoyl-CoA Desaturase
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Lactobacillus casei Bd-II stain and used to reduce blood cholesterol
The invention disclosed a kind of lactobacillus casei Bd-II, the accession number of the deposit of which is CGMCC NO.0849, and also disclosed a use of it for reducing blood lipid level. Further, a composition for reducing blood lipid level containing it and an acceptable carrier is disclosed. The carrier can be skimmed milk.
Owner:BRIGHT DAIRY & FOOD CO LTD
SARS Vaccine Compositions and Methods of Making and Using Them
InactiveUS20090017069A1The process is simple and effectiveThe method is simple and efficientSsRNA viruses positive-senseViral antigen ingredientsLipid formationViral Vaccine
Owner:ELI LILLY & CO +1
Pharmaceutical compositions containing exendins
InactiveUS20050215469A1Reduce appetiteReduce cardiac riskPeptide/protein ingredientsMetabolism disorderBlood plasmaInsulin resistance
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:ASTRAZENECA PHARMA LP
Use of exendins and agonists thereof for lowering plasma lipid
InactiveUS20050101537A1Reduce appetiteReduce cardiac riskPeptide/protein ingredientsMetabolism disorderBlood plasmaInsulin resistance
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:AMYLIN PHARMA INC
Immune type protein powder solid beverage and preparation method thereof
ActiveCN104522832AImprove absorption rateHigh purityNatural extract food ingredientsFood ingredient functionsWhey proteinGamma-Aminobutyric acid
The invention discloses an immune type protein powder solid beverage and a preparation method thereof and belongs to the field of nutritional foods. The solid beverage comprises the following components: 70-85 percent of concentrated whey protein powder, 3-8 percent of pea protein, 5-15 percent of wheat protolysate, 2-4 percent of phospholipid, 1-3 percent of an acerola cherry extract, 1-5 percent of edible essence, 0.5-1.5 percent of a yeast extract, 0.5-1.5 percent of gamma-aminobutyric acid, 0.5-1.5 percent of coconut milk powder, 0.3-0.8 percent of silicon dioxide and 0.1-0.3 percent of stevioside. The invention also discloses the preparation method of the solid beverage. The solid beverage disclosed by the invention fully meets the demands of the human body, is scientific in prescription design, reasonable in nutrition arrangement and different in taste according to different customers, and can meet the special demands of different people on taste; the solid beverage is mellow in taste, convenient to use, stable in quality, simple in preparation method, easy to operate, suitable for large-scale industrial production, free of sugar in the prescription and suitable for diabetics to eat.
Owner:JIANGSU ALAND NOURISHMENT
Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of Stearoyl-Coadesaturase (Scd)
InactiveUS20070219211A1Lower blood lipid levelsEffective to modulate triglyceride levelBiocideOrganic chemistryDiseaseHeterocyclic derivatives
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise, for example, administering to a mammal in need thereof a compound of formula (I): where x, y, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
ActiveUS7393826B2Low in lipidsLower blood lipid levelsBiocideOrganic active ingredientsPresent methodCellular cholesterol
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
Owner:HDL THERAPEUTICS +1
Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
InactiveUS20150072962A1High expressionLower Level RequirementsBiocideOrganic active ingredientsFatty liverDiabetes mellitus
5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARγ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.
Owner:VIRGINIA COMMONWEALTH UNIV +1
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
ActiveUS20060172939A1Reduced lipid contentIncrease capacityOrganic active ingredientsBiocideATHEROSCLEROTIC VASCULAR DISEASEStatine
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.
Owner:HDL THERAPEUTICS +1
Compositions and methods for treatment of insulin-resistance diseases
InactiveUS20090029904A1Reduced glucose levelLower blood lipid levelsOrganic active ingredientsBiocideDiseaseOxidative stress
Compositions and methods are provided for modulation of Target of Rapamycin (TOR) activity. Reduction of TOR blocks insulin resistance and metabolic syndrome phenotypes caused by expression of a constitutively activated version of the insulin responsive transcription factor, FOXO. These TOR-mediated responses are also linked with protection against age-dependent functional organ senescence, e.g., heart decline, as well as increased longevity without changes in resistance to starvation and oxidative stresses.
Owner:BURNHAM INST FOR MEDICAL RES
Clinical nutritional formula special for kidney dialysis and preparation method thereof
InactiveCN108651988AImprove cleanlinessRepair functionVitamin food ingredientsLipidic food ingredientsOxygenKidney
The invention provides a clinical nutritional formula special for kidney dialysis. The clinical nutritional formula special for kidney dialysis comprises the following components in parts by weight: 15-25 parts of protein, 8-12 parts of fat, 50-54 parts of carbohydrate, 3-5 parts of dietary fiber, 0.3-0.6 part of macro-elements, 0.01-0.05 part of trace elements, 0.005-0.02 part of fat-soluble vitamin, 0.01-0.2 part of water-soluble vitamin, 0.05-1 part of dietary essence, 0.05-2 parts of medicinal and edible components, 0.1-3 parts of natural plant compounds, and 0.005-2 parts of new resourcefood; and the invention also provides a preparation method of the clinical nutritional formula. The clinical nutritional formula special for kidney dialysis provided by the invention can provide balanced nutrient substances for patients with renal dialysis, and can maintain the stability of the body quality of the patient, enhance the ability of immune response and the repair function, reduce inflammation, and improve the activity of scavenging oxygen free radicals and the endothelial cell function.
Owner:上海奥医生物医药科技有限公司
Method for producing cereal diet fiber of high soluble diet fiber content
The production process of cereal diet fiber with high soluble diet fiber content has lactic acid bacteria fermentation to replace traditional acid and alkali treatment, ultra high pressure homogenization to replace traditional processing and final spray drying to obtain ultimate product. The present invention features the lactic acid bacteria fermentation capable of loosening diet fiber and favorable to subsequent processing and maintaining the water binding capacity and function of diet fiber, the high pressure homogenization on the basis of fermentation to reduce the granularity of diet fiber to below 40 micron and to eliminate the roughness feeling of diet fiber, and simple production process easy to use in industrial production.
Owner:NANCHANG UNIV
Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
ActiveUS20100273761A1Improve suppression propertiesDecrease lipid biosynthesisOrganic active ingredientsAntipyreticLipid formationMetabolite
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Combinations of Botanical Extracts for Promoting Cardiovascular Health
InactiveUS20100239603A1Eliminate side effectsEfficacyBiocideNervous disorderAcute hyperglycaemiaNervous system
A blood lipid lowering agent that functions through a same mechanism as berberine (e.g. berberine, one or more pharmacologically acceptable salts of berberine or a mixture thereof) and a blood lipid lowering agent that functions through a different mechanism than berberine (e.g. phytosterols, phytostanols, esters thereof or mixtures thereof) act synergistically to improve blood lipid profiles, for example, lowering total cholesterol, LDL-C or nonHDL-C, and triglyceride, and increasing the ratio of HDL-C to nonHDL-C. The two may be used in combination to treat or reduce the chance of contracting cardiovascular disease, hyperlipidemia, atherosclerosis, coronary heart disease, angina, cerebrovascular disease, stroke, overweight or obesity, diabetes, insulin resistance, hyperglycemia, hypertension, arrhythmia, diseases of the central nervous system, diseases of the peripheral nervous system and / or inflammation. The blood lipid lowering agent that functions through a same mechanism as berberine, with or without the blood lipid lowering agent that functions through a different mechanism than berberine, may also be used to control weight.
Owner:NAT RES COUNCIL OF CANADA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com